The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is soaring to yearly highs on the back of positive phase three clinical trial results.
Shares are currently swapping hands at $3.40 apiece, up exactly 100% from yesterday’s close.
Let’s investigate what triggered the major boost for the drug therapy company today.
Why did Neuren announce?
Neuren reported positive results from phase three trials into the use of trofinetide to treat young women with Rett syndrome. Trofinetide has been granted fast-track status and orphan drug designation for Rett syndrome.
Acadia Pharmaceuticals (NASDAQ: ACAD) is conducting and funding the trials, but Neuren is eligible to receive milestone payments of up to US$455 million (AU$645 million). Neuren is also eligible for royalties on trofinetide sales if the drug is approved by the FDA.
Acadia is planning to meet with the FDA for a new drug application in the middle of 2022.
Neuren predicts it would earn AU$111 million in revenue over 2022 and 2023 for Rett syndrome, plus double-digit percentage royalties on net sales if trofinetide is approved and launched in the US.
Rett syndrome is a rare genetic mutation affecting brain development, primarily in girls.
What did management say?
Commenting on the news driving the Neuren Pharmaceuticals share price today, CEO Jon Pilcher said:
We are delighted with these robustly positive results and are now eager to see trofinetide progress through the regulatory approval process.
We are very grateful to the Rett syndrome community — the patients, their caregivers, study site personnel, physicians and everyone who participated in the Lavender study, as well as in Neuren’s two Phase 2 studies that paved the way.
Neuren Pharmaceuticals share price snapshot
The Neuren Pharmaceuticals share price has skyrocketed 164% this year to date. It has also gained 170% over the past 12 months.
Earlier today, the share price reached $3.56, a yearly high. The yearly low is $1.18.
The post Neuren Pharmaceuticals (ASX:NEU) share price rockets 100% on study results appeared first on The Motley Fool Australia.
Should you invest $1,000 in Neuren Pharmaceuticals right now?
Before you consider Neuren Pharmaceuticals, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Neuren Pharmaceuticals wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
More reading
- Oil Search (ASX:OSH) shareholders give green light for Santos merger
- What happened for the ANZ (ASX:ANZ) share price in November?
- ASX 200 (ASX:XJO) midday update: Zip update impresses, BOQ rises
- Missed out on Ethereum? Here’s a possible alternative
- This crypto will outperform both Bitcoin and Ethereum in 2022: expert
The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/3lEaZzG
Leave a Reply